# OnCo record topaz-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/topaz-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "topaz-1", "NCT03875235" ;
  schema:name "TOPAZ-1"@en ;
  schema:description "TOPAZ-1 was the first immunotherapy success in bile duct cancer, with a small median gain but a growing tail of long survivors."@en ;
  schema:url <https://onco.cc/trials/topaz-1/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03875235>, <https://pubmed.ncbi.nlm.nih.gov/38823398/>, <https://www.journal-of-hepatology.eu/article/S0168-8278(25)02201-9/fulltext>, <https://www.nice.org.uk/guidance/ta944>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22IMFINZI%22>, <https://www.nice.org.uk/guidance/ta944>, <https://doi.org/10.1016/j.jhep.2025.05.003> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2019-04-16" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:people <https://onco.cc/people/juan-valle/>, <https://onco.cc/people/oh-do-youn/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-topaz-1-nejm-evidence-2022/>, <https://onco.cc/key-papers/paper-topaz-1-lancet-gastroenterol-hepatol-2024-update/> .